This section explains what ФИССАРИО treats, the main symptoms it helps manage, and the key patient benefits it provides.

---

Primary Treatment for IgA Nephropathy (IgAN)

This medication is used to manage a specific chronic autoimmune kidney condition known as Immunoglobulin A Nephropathy (IgAN). It is commonly used in adult patients with primary IgAN who are considered at risk for disease progression. The treatment is commonly used to help manage the disease process and may assist with maintaining functional stability.

Reducing Protein Leakage in Urine (Proteinuria)

The treatment is applied across domains where additional symptomatic support is needed, with a primary effect being the reduction of proteinuria (high levels of protein leaking into the urine). This action is relevant for easing symptoms associated with chronic kidney conditions. By reducing this leakage, the treatment helps manage symptoms that create noticeable physiological strain by moderating a measurable manifestation of kidney malfunction. It is considered relevant for easing symptoms in IgAN and the associated symptom cluster of proteinuria. Its clinical application is based on the reduction of proteinuria.

“This approach supports patients during episodes of heightened discomfort and assists with maintaining functional stability.”

This treatment contributes to improved comfort during symptomatic periods, supporting general well-being.

Quick Fact: Addressing Proteinuria
This medication is used to address the measurable symptom of protein in the urine.

ФИССАРИО is authorized for use primarily in adults between 18 and 65 years old for specific conditions, according to regulatory guidelines. Eligibility is defined by a set of strict contraindications and population restrictions based on potential systemic risks.

Contraindicated Populations (Must Not Use)

The medicine is strictly prohibited for individuals with:

• A known allergy or hypersensitivity to the active ingredients (lidocaine or nifedipine) or related drug classes.
• Pregnancy, planning to become pregnant, or lactation (breastfeeding).
• Severe cardiac conditions, including severe hypotension, cardiac insufficiency, unstable angina, recent myocardial infarction, or cardiovascular shock.
• Specific hematological disorders, such as congenital or idiopathic methemoglobinemia, or Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
• Concomitant treatment with diltiazem.

Age and Population Restrictions

• Pediatrics (< 18 years): Use is not authorized or not established as safety and effectiveness data are not available.
• Older Adults (> 65 years): Use is conditional and requires caution and close monitoring due to the potential for increased sensitivity to systemic exposure.

Interactions with other medicines and products

Official regulatory documents define specific drug interaction constraints based on the potential for altered plasma concentrations or increased risk of bleeding.

Critical Pharmacokinetic Interactions

Concomitant use with agents that are combined inhibitors of P-glycoprotein (P-gp) and the enzyme CYP3A4 (e.g., ketoconazole, ritonavir) is required to be avoided. This combination significantly increases the exposure of ФИССАРИО, which elevates the risk of hemorrhage.

Similarly, concomitant use with combined inducers of P-gp and CYP3A4 (e.g., rifampin, St. John's wort) is required to be avoided. This combination decreases drug exposure, potentially increasing the risk of thrombotic events.

Hemostasis-Affecting Interactions

Co-administration with other medicines that affect blood clotting or platelet function can increase the overall risk of bleeding. This includes other anticoagulants (e.g., heparin, warfarin), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), platelet aggregation inhibitors (e.g., aspirin), and certain antidepressants like Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). Use with these agents requires close clinical observation and assessment for signs of blood loss.

Use with moderate CYP3A4/P-gp inhibitors (e.g., erythromycin, diltiazem) requires caution due to increased exposure, particularly in patients with compromised kidney function. Regulatory labels include specific requirements for transitioning to or from other anticoagulant therapies.

The mechanism of action for ФИССАРИО relies on the combined, complementary influence of its two active ingredients on peripheral nerve transmission and smooth muscle contraction.

---

Modulating Local Nociceptive Signal Transmission

This core mechanistic domain involves Lidocaine's ability to engage and block voltage-gated sodium channels (NaV) on sensory nerve fibers. By preventing the necessary influx of Na^+ ions, the drug directly interrupts the electrical cascade required for action potential propagation, resulting in the local prevention of afferent signal conduction.

---

Inhibiting Smooth Muscle Excitation and Tone

The second domain centers on Nifedipine, which acts as an antagonist on L-type calcium channels (Ca^2+) in smooth muscle cells. This action limits the availability of intracellular Ca^2+, which is the necessary ion for initiating the contractile mechanism. This molecular event leads to the relaxation of muscle fibers, which decreases baseline smooth muscle tone and facilitates localized vasodilation.

---

Dual-Action Pharmacodynamic Synergy

The final domain highlights the combined physiological effect: the sodium channel blockade prevents afferent signal transmission, while the calcium channel antagonism modulates smooth muscle tone and microcirculatory dynamics. This synergistic approach targets both the afferent sensory pathway and efferent physiological processes, defining the combined mechanism of action.

Official Administration Guidelines

The administration of ФИССАРИО, a fixed-dose combination topical cream containing Nifedipine 0.3% and Lidocaine Hydrochloride 1.5%, is strictly governed by the official instructions outlined in regulatory documentation. The approved route of administration is exclusively topical and rectal/perianal, intended for highly localized delivery. It is expressly designated for external use and must not be taken orally.

Standard Dosing and Schedule

The standardized adult dosing regimen specifies an application of one centimeter of cream per dose. This measured amount is administered twice daily, approximately every 12 hours. The official guidance directs that the cream is to be applied up to one centimeter inside the anus or around the perianal area. Prior to each use, the affected area must be cleaned and dried. The typical recommended course of treatment duration is established as three weeks.

Procedural Rules and Population Constraints

The procedural protocol for timing addresses missed applications by mandating that the dose be skipped, with the subsequent application resuming at the regularly scheduled time; a double amount must not be administered to compensate. Specific regulatory constraints exist for administration in certain age groups. For geriatric patients (over 65 years of age), close monitoring is warranted due to the potential for increased systemic effects from the lidocaine component. Conversely, the use of the cream is not authorized for pediatric patients under 18 years of age, as sufficient safety and efficacy data for this population are unavailable to the authorizing agency.

Research Evidence / Overview of Studies for ФИССАРИО

---

Evidence for Use in Chronic Anal Fissure

Research for the topical combination of Lidocaine and Nifedipine has primarily evaluated chronic anal fissure, a condition characterized by painful symptoms and functional limitations. The available evidence largely stems from short-term, randomized controlled trials (RCTs), with subsequent systematic reviews also available. These studies were designed to observe patterns associated with the combination in adult patients whose symptoms often persisted for many weeks.

Research examined outcomes related to physical discomfort, using studies that monitored patient-reported experiences of pain. Researchers also included objective measurements, such as monitoring changes in the anal resting pressure using specialized equipment. Findings describe patterns measured during the short-term study period (typically 6 weeks). Compared to inactive or placebo applications, some trials reported patterns of healing rates compared to placebo groups in short-term evaluations.

---

Research Comparing ФИССАРИО to Other Topical Treatments

Several studies explored how ФИССАРИО was evaluated against other non-surgical therapies commonly used for chronic anal fissure, such as single-agent topical anesthetics or other muscle-relaxing agents. These comparative trials were conducted to assess measurements of outcomes against other established or active topical controls. Findings describe patterns observed in these comparative studies concerning healing rates and symptom intensity. Evidence contributes to the broader evidence landscape but research provides context but not individual predictions regarding comparative results.

---

⏱️ Long-Term Studies and Durability of Response

While the initial randomized controlled trials focused primarily on short-term changes—often reporting results after approximately six weeks—the research also monitored how symptoms evolved in the observed populations beyond that immediate phase. However, a key limitation in the research is that long-term outcomes are not fully established. Data for extended follow-up periods, particularly those monitoring the rates of fissure recurrence beyond one year, remain insufficient.

---

What is Still Uncertain About ФИССАРИО

The evidence landscape, while defined for chronic anal fissure, still contains areas where data are limited. Follow-up durations were limited in many pivotal trials, and subgroup findings are uncertain due to modest sample sizes in specific patient groups. Evidence quality varies across studies regarding the precise formulation used; this heterogeneity leads to variability in reported findings.

Furthermore, the official research base was not studied for this specific topical Lidocaine/Nifedipine combination in the context of any systemic kidney condition, such as IgA Nephropathy (IgAN). There is no formal clinical trial evidence or regulatory submission that describes the observation of this topical medication's use in patients with IgAN.

Common questions about ФИССАРИО (FAQ)

---

Q: How quickly can I expect ФИССАРИО to start working?

A: Official product information describes the intended effects of the two active ingredients. The Lidocaine component, a local anesthetic, is designed to provide a rapid onset of localized pain relief by temporarily blocking nerve signals at the application site. The Nifedipine component works to relax muscle tone, and the time required to experience its physiological effect may vary.

Q: Is it true that ФИССАРИО can cause a metallic taste?

A: A metallic taste is not generally listed among the common or expected side effects of this topical medication. However, in very rare instances of severe systemic absorption of Lidocaine, a component of ФИССАРИО, general systemic symptoms like taste disturbance can potentially occur. Systemic absorption refers to when the medicine enters the bloodstream in higher-than-expected amounts.

Q: Can ФИССАРИО affect my ability to drive or operate machinery?

A: According to official labeling, the possibility of severe systemic effects must be considered. Although rare with topical use, excessive absorption of the Lidocaine component can lead to Central Nervous System (CNS) effects, such as somnolence (drowsiness) or convulsions. Regulatory information indicates caution is advised regarding these potential effects when performing tasks that require full alertness, such as driving or operating machinery.

Q: Is it necessary to finish the entire course of ФИССАРИО even if I feel better?

A: The officially recommended treatment duration for ФИССАРИО is typically three weeks. Regulatory guidance specifies this course length to maximize the likelihood of achieving the intended therapeutic benefit. Discontinuing the product earlier than prescribed may impact the consistency of the treatment effect, based on regulatory guidance for the recommended course duration.

Q: Is ФИССАРИО considered a controlled substance?

A: Official drug classifications identify ФИССАРИО as a prescription-only medication. However, based on the federal scheduling of drugs, this product is not typically classified as a controlled substance.

Q: What are the official warnings about using alcohol with ФИССАРИО?

A: The regulatory label does not specifically list alcohol as a direct interaction requiring avoidance. However, regulatory documents note that alcohol consumption may contribute to an increased likelihood of systemic effects, particularly hypotension (low blood pressure), due to the presence of the Nifedipine component.

Q: How is the safety of ФИССАРИО monitored after it is released?

A: The safety profile of ФИССАРИО is subject to continuous monitoring through national pharmacovigilance systems. These systems require healthcare professionals and manufacturers to report any adverse events observed after the product has been released to the public.

Q: Can taking ФИССАРИО make certain lab test results inaccurate?

A: Official labeling does not contain general warnings about interference with routine clinical laboratory tests. However, it is recognized that the use of any medication may have physiological effects that could influence specific diagnostic test results.

Q: What happens to ФИССАРИО in the body after it is taken (metabolism)?

A: After application, the active ingredients are absorbed locally, with some potential for minimal systemic absorption. The Lidocaine component is primarily metabolized (broken down) in the liver. Due to this process, regulatory caution is noted for individuals with hepatic impairment, reflecting that the body's ability to clear the drug may be reduced in this population.

Q: What is the shelf life of ФИССАРИО?

A: The shelf life for ФИССАРИО is determined by the manufacturing company and is clearly marked as an expiration date on the product packaging. To ensure the product maintains its effectiveness and stability, it must be stored according to the specified controlled room temperature and handling conditions.

Q: Does ФИССАРИО contain gluten or common allergens?

A: Regulatory labeling requires the manufacturer to provide a full list of all inactive ingredients (excipients) in the product. These are the non-medicinal components, such as the base cream or stabilizers, used to create the topical form. However, official drug information does not typically guarantee the complete absence of all potential common allergens, such as gluten.

Q: How long does ФИССАРИО stay in your system after the last intake?

A: The active components, Lidocaine and Nifedipine, have specific elimination half-lives in the body. Following the recommended topical application, the residual systemic levels are generally considered minimal due to the product’s localized effect. The elimination rate depends on individual metabolic function.

Q: What should be done if someone accidentally takes too much ФИССАРИО?

A: The regulatory document includes information on the risks associated with overdosage. Overexposure could lead to severe systemic effects, particularly those affecting the Central Nervous System and cardiovascular system. In the event of an accidental overdosage, regulatory documents indicate that supportive and symptomatic treatment is generally recommended.

Q: Is there a risk of dependency or withdrawal symptoms with ФИССАРИО?

A: According to official product information, ФИССАРИО is not associated with the risk of physical or psychological dependence. There are no known or documented withdrawal symptoms associated with the discontinuation of this product.

Q: Can ФИССАРИО make existing skin conditions worse?

A: Common side effects listed in the official safety profile include local application site reactions such as irritation, redness (erythema), and itching (pruritus). These local effects are typically transient but may resemble or overlap with symptoms of pre-existing skin conditions in the area where the product is applied.

How to Store and Dispose of ФИССАРИО

ФИССАРИО (Lidocaine/Nifedipine Topical Ointment) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with allowed excursions up to 30 C. It is mandatory to store the ointment in its original container, keep the cap tightly closed, and ensure it is protected from light, excessive heat, and freezing to maintain product stability.

Child Safety and Disposal

The medicine must be stored strictly out of the sight and reach of children. Any unused or expired ФИССАРИО must not be disposed of in household waste or flushed down a toilet. Disposal must comply with local requirements for pharmaceutical waste, typically by returning the product to a pharmacy or using an official drug take-back program.